On May 10, 2023 Step Pharma, the world leader in CTPS1 inhibition for the targeted treatment of cancer, reported that members of its management team will be participating at a number of conferences in May and June 2023 (Press release, Step Pharma, MAY 10, 2023, View Source [SID1234631401]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

By targeting CTPS1, an enzyme that catalyses a rate-limiting step in pyrimidine synthesis, Step Pharma has unlocked the ability to selectively inhibit the de novo pyrimidine synthesis pathway, enabling a highly selective treatment of cancer.

23rd Bio€quity Europe, Dublin, Ireland, 15-16 May & 22-23 May Digital Partnering

In person corporate presentation by Andrew Parker, CEO at 1.28pm on 5 May

2023 ASCO (Free ASCO Whitepaper) Annual Meeting, Chicago, IL, US, 2-6 June

Poster presentation: A phase 1/2 study of STP938, a first-in-class inhibitor of CTP synthase 1, in patients with relapsed/refractory B or T cell lymphoma.
Authors: Manish Patel, Matthew Ahearne, Kim Linton, Christopher Fox, David Lewis, Maureen Higgins, Brian Schwartz, Philip Beer, Michael Tees

Session Title: Hematologic Malignancies – Lymphoma and Chronic Lymphocytic Leukemia

Session Date and Time: 6/5/2023, 8:00 AM-11:00 AM CST

Track: Hematological Malignancies

Subtrack: Non-Hodgkin Lymphoma

Clinical Trial Registration Number: NCT05463263

Abstract #TPS7591

Poster Bd #135b

BIO International Convention Congress, Boston, MA, US, 5-8 June

International Conference of Malignant Lymphoma, Lugano, Switzerland, 13-17 June